INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuti ...

In April 2025, the FDA granted orphan drug designation to spesolimab-sbzo for the treatment of pyoderma gangrenosum. This ...

These four Dividend Aristocrats are Buy-rated sector leaders with yields above 3%. Passive income investors can buy and hold ...

After underperforming the overall market for the past few years, large-cap pharmaceutical stocks may now be positioned to ...

InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now. As May came to an end, InflaRx announced that its ...

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: "We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this ...

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this ...

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this ...

JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...

Although his prognosis is still unknown — given that pyoderma gangrenosum remains poorly understood by scientists — Johns Hopkins gave Ryan the grim prediction in February that he likely has ...

Pyoderma gangrenosum (PG), a rare inflammatory skin disease, had been challenging to diagnose due to its nonspecific histological characteristics. Researchers conducted a retrospective study to ...